Abbott Laboratories (NYSE:ABT) Receives “Buy” Rating from BTIG Research

BTIG Research reiterated their buy rating on shares of Abbott Laboratories (NYSE:ABT) in a report published on Monday,Benzinga reports. BTIG Research currently has a $131.00 price objective on the healthcare product maker’s stock.

Several other analysts also recently commented on ABT. Jefferies Financial Group dropped their target price on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Piper Sandler dropped their target price on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Bank of America dropped their target price on shares of Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Citigroup dropped their target price on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Finally, Daiwa Securities Group downgraded shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price on the stock. in a report on Wednesday, April 22nd. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $119.43.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT opened at $92.85 on Monday. The company has a market capitalization of $161.71 billion, a price-to-earnings ratio of 26.01, a P/E/G ratio of 1.52 and a beta of 0.79. The firm’s 50 day simple moving average is $105.56 and its 200 day simple moving average is $116.83. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a fifty-two week low of $90.72 and a fifty-two week high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. Abbott Laboratories’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period last year, the company posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was bought at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the purchase, the director directly owned 6,738,817 shares of the company’s stock, valued at $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the transaction, the senior vice president directly owned 39,164 shares of the company’s stock, valued at $4,526,575.12. This represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Abbott Laboratories

Hedge funds have recently made changes to their positions in the business. Nia Impact Advisors LLC increased its holdings in Abbott Laboratories by 2.2% during the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after buying an additional 79 shares during the last quarter. Global Financial Private Client LLC increased its holdings in Abbott Laboratories by 3.3% during the third quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after buying an additional 79 shares during the last quarter. Citizens & Northern Corp increased its holdings in Abbott Laboratories by 0.4% during the third quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock worth $2,930,000 after buying an additional 79 shares during the last quarter. American National Bank of Texas increased its holdings in Abbott Laboratories by 2.4% during the fourth quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock worth $427,000 after buying an additional 79 shares during the last quarter. Finally, Nova R Wealth Inc. increased its holdings in Abbott Laboratories by 3.0% during the third quarter. Nova R Wealth Inc. now owns 2,802 shares of the healthcare product maker’s stock worth $375,000 after buying an additional 81 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.